St2 antigen binding proteins
US-2024368292-A1 · Nov 7, 2024 · US
Agonist antibody to human thrombopoietin receptor
US8999329B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8999329-B2 |
| Application number | US-201213543183-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 6, 2012 |
| Priority date | Mar 23, 2006 |
| Publication date | Apr 7, 2015 |
| Grant date | Apr 7, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention provides an agonist antibody to a human thrombopoietin receptor (human c-Mpl), and pharmaceutical compositions comprising the same for use in treatment of thrombocytopenia. The disclosed agonist antibody comprises (1) antibody constant regions comprising heavy and light chain constant regions, each of which may optionally contain domain substitutions, or may contain deletions, substitutions, additions, or insertions of amino acid residues, and (2) antibody variable regions capable of binding to and activating a human thrombopoietin receptor. The-agonist antibody further induces colony formation at a concentration of 10,000 ng/ml or lower, and has a maximal activity at least 50% higher than that of PEG-rHuMGDF and an 50% effective concentration (EC50) of 100 nM or less.
First claim
Opening claim text (preview).
The invention claimed is: 1. An agonist antibody, wherein said agonist antibody comprises a heavy chain comprising a constant region and a variable region, and a light chain comprising a constant region and a variable region, wherein the heavy- and light-chain variable regions form an antigen-binding domain with agonist activity, and wherein the heavy chain constant region comprises all of (i)-(iv): i) an upper hinge portion comprising the amino acid sequence of ELKTPLGDTTHT (…
Assignees
Inventors
Classifications
Chemistry & Metallurgy · mapped topic
- C07K16/2866Primary
Chemistry & Metallurgy · mapped topic
Cross-Sectional Technologies · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8999329B2 cover?
- This invention provides an agonist antibody to a human thrombopoietin receptor (human c-Mpl), and pharmaceutical compositions comprising the same for use in treatment of thrombocytopenia. The disclosed agonist antibody comprises (1) antibody constant regions comprising heavy and light chain constant regions, each of which may optionally contain domain substitutions, or may contain deletions, su…
- Who is the assignee on this patent?
- Kai Masayuki, Motoki Kazuhiro, Kataoka Shiro, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2866. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 07 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).